Source: DGNews | Posted 9 years ago
Long-Term Fosrenol (Lanthanum Carbonate) Controls Harmful Phosphate in End-Stage Kidney Disease
Tags:
Phase Three Trial Data of Novel, Non-Calcium Lanthanum Carbonate Presented at National Kidney Foundation Meeting
DALLAS, TX -- April 4, 2003 -- Shire Pharmaceuticals Group plc (Nasdaq: SHPGY, LSE: SHP.L, TSE: SHQ CN) announced that continued, long-term treatment (one-year) with Fosrenol
Comments